REGN1908-1909 for Allergic Eye
Trial Summary
What is the purpose of this trial?
This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you have ongoing allergen immunotherapy with any allergen other than cat, you may be excluded from participating.
What data supports the idea that REGN1908-1909 for Allergic Eye is an effective treatment?
The available research does not provide specific data on the effectiveness of REGN1908-1909 for Allergic Eye. Instead, it discusses other treatments for ocular allergies, such as anti-histamines, mast cell stabilizers, and steroids, which are used to manage symptoms. These treatments vary in potency and side effects, with steroids being very potent but having serious side effects. Without specific data on REGN1908-1909, we cannot compare its effectiveness to these alternatives.12345
What safety data is available for REGN1908-1909 treatment?
Research Team
Clinical Trial Management
Principal Investigator
Regeneron Pharmaceuticals
Eligibility Criteria
Adults with a history of moderate to severe cat allergy for at least 2 years, confirmed by skin and blood tests. Participants must have significant eye allergy symptoms when near cats, not live with cats for the past 3 years, and avoid contact with cats during the trial.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the study drug REGN1908-1909 or placebo to assess efficacy and safety in reducing ocular allergy signs and symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of ocular symptoms and immune response
Treatment Details
Interventions
- REGN1908-1909
Find a Clinic Near You
Who Is Running the Clinical Trial?
Regeneron Pharmaceuticals
Lead Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School